Abstract
MicroRNAs have been predicted to regulate the stability and translation of many target mRNAs that are involved in modulating disease outcome. Thus, valuable strategies to enhance or to diminish the function of microRNAs are needed to manipulate microRNA-mediated target gene expression. Recently, it has become apparent that one class of antisense oligonucleotides, locked nucleic acids, can be used to sequester microRNAs in the liver of a variety of animals including humans, opening the possibility of applying locked nucleic acid-mediated gene therapy. This review summarizes the success of sequestration of liver-specific microRNA miR-122 by antisense locked nucleic acids and their use in combating hepatitis C virus in clinical trials.
Keywords: Clinical trials, gene targeting, hepatitis C virus, locked nucleic acids, microRNA-mRNA interactions, viral gene expression.
Current Gene Therapy
Title:Combating Hepatitis C Virus by Targeting MicroRNA-122 Using Locked Nucleic Acids
Volume: 12 Issue: 4
Author(s): Erica S. Machlin, Peter Sarnow and Selena M. Sagan
Affiliation:
Keywords: Clinical trials, gene targeting, hepatitis C virus, locked nucleic acids, microRNA-mRNA interactions, viral gene expression.
Abstract: MicroRNAs have been predicted to regulate the stability and translation of many target mRNAs that are involved in modulating disease outcome. Thus, valuable strategies to enhance or to diminish the function of microRNAs are needed to manipulate microRNA-mediated target gene expression. Recently, it has become apparent that one class of antisense oligonucleotides, locked nucleic acids, can be used to sequester microRNAs in the liver of a variety of animals including humans, opening the possibility of applying locked nucleic acid-mediated gene therapy. This review summarizes the success of sequestration of liver-specific microRNA miR-122 by antisense locked nucleic acids and their use in combating hepatitis C virus in clinical trials.
Export Options
About this article
Cite this article as:
Machlin S. Erica, Sarnow Peter and Sagan M. Selena, Combating Hepatitis C Virus by Targeting MicroRNA-122 Using Locked Nucleic Acids, Current Gene Therapy 2012; 12 (4) . https://dx.doi.org/10.2174/156652312802083558
DOI https://dx.doi.org/10.2174/156652312802083558 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Advancements in Treatment Options of Women Infertility
Current Women`s Health Reviews Is Later Obesity Programmed In Utero?
Current Drug Targets Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Vascular Inflammation During Human Rickettsioses: An Essential Host Response and a Potential Target for Supplemental Therapy
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mechanisms of Endogenous Endothelial Repair in Stroke
Current Pharmaceutical Design Genetic Risk Factors in Cerebrovascular Disorders and Cognitive Deterioration
Current Genomics In Silico Classification and Prediction of VIP Derivatives as VPAC1/ VPAC2 Receptor Agonists/Antagonists
Combinatorial Chemistry & High Throughput Screening Novel Promising Therapeutic Agents in Multiple Sclerosis
Recent Patents on Inflammation & Allergy Drug Discovery Unraveling the Action Mechanism of Buyang Huanwu Tang (BYHWT) for Cerebral Ischemia by Systematic Pharmacological Methodology
Combinatorial Chemistry & High Throughput Screening Transgenerational Inheritance in the Offspring of Pregnant Women with Metabolic Syndrome
Current Pharmaceutical Biotechnology Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Traditional and Novel Risk Factors of Diabetic Retinopathy and Research Challenges
Current Medicinal Chemistry Macrophages: Promising Targets for the Treatment of Atherosclerosis
Current Vascular Pharmacology Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Effects of Vitamin C and E Against Oxidative Stress: Is Antioxidant Supplementation Efficient?
Current Nutraceuticals A Brief History of ‘Lone’ Atrial Fibrillation: From ‘A Peculiar Pulse Irregularity’ to a Modern Public Health Concern
Current Pharmaceutical Design Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety